AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

Inc. ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

A collaborative study led by Prof. Liu Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. Wang ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

There was a dose-dependent, transient increase in serum ALT concentrations using the lentiviral vector not encoding accessory proteins (Fig. 3). In addition, the 8–10×10 8 TU dose of vector was ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...